시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 클라미디아 감염 치료 시장 보고서(2025년)
Chlamydia Infection Treatment Global Market Report 2025
상품코드 : 1825667
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,546,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,462,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,378,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

클라미디아 감염 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.9%로 성장할 전망이며, 44억 2,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 계발 캠페인, 고액 의료비, 청소년 성인의 이환율 상승, 규제 당국의 승인, 헬스케어 인프라 확대, 항생제 내성의 이환율 상승에 기인할 것으로 예측됩니다. 예측 기간 주요 동향으로는 진단 기술의 진보, 포인트 오브 케어 검사 개발, 공동 연구 및 파트너십, 효과적인 치료법 개발, 기술의 진보 등이 있습니다.

향후 5년간의 성장률 7.9%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 무역 마찰로 인해 캐나다와 스위스에서 개발된 독시사이클린 정제 및 아지트로마이신 단회 투여 팩의 가격이 상승하고, 치료 지연 및 지역 의료 센터의 비용 증가를 초래하는 등 미국의 항생제 스튜어드십이 저해될 수 있습니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.

성감염증(STDs)의 만연 증가는 클라미디아 감염 치료 시장의 성장을 가속할 것으로 예측됩니다. STD는 질, 항문, 구강 섹스와 같은 성적 접촉을 통해 일반적으로 퍼지는 감염입니다. 이러한 STD 감염률의 상승은 콘돔과 같은 장벽 수단에 있어서 일관성의 부족과 잘못된 사용, 안전한 성행위에 대한 인식 및 교육의 불충분성, 예방 이니셔티브를 위한 공중위생 자금의 잠재적 감소 등이 원인이 되고 있습니다. 클라미디아 감염의 진단 및 치료제는 조기 발견과 효과적인 치료를 지원하고 합병증의 예방과 감염을 줄이기 위해 STDs 관리에 필수적입니다. 예를 들어, 2024년 5월, 스위스에 본부를 두고 있는 정부간 기관인 세계보건기구(WHO)의 보고서는 치료 가능한 4가지 성병(매독, 임질, 클라미디아, 트리코모나스)이 매일 100만 명 이상의 감염자를 차지하고 있다고 강조했습니다. 또한 보고서는 성인 매독과 모체 매독 증례(110만 명) 증가와 연관된 선천성 매독 증례 증가를 지적합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Treatment for Chlamydia infection involves medical methods and therapies aimed at curing the infection caused by Chlamydia trachomatis. Chlamydia is a prevalent sexually transmitted infection (STI) that can impact both men and women, potentially leading to serious health issues if not addressed. The main objectives of treatment are to eradicate the infection, alleviate symptoms, and avoid complications.

The primary methods for diagnosing and treating chlamydia infections include chlamydia culture, urine culture, enzyme immunoassays, and nucleic acid amplification tests. Chlamydia culture involves growing Chlamydia bacteria in a controlled lab setting using cells from a sample. The infection can be caused by organisms such as Chlamydia trachomatis and Chlamydophila pneumoniae, among others. Treatment can be administered orally, by injection, or through other methods, and is provided in various settings including hospitals, homecare environments, specialty clinics, and other locations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The chlamydia infection treatment market research report is one of a series of new reports from The Business Research Company that provides chlamydia infection treatment market statistics, including chlamydia infection treatment industry global market size, regional shares, competitors with a chlamydia infection treatment market share, detailed chlamydia infection treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia infection treatment industry. This chlamydia infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chlamydia infection treatment market size has grown strongly in recent years. It will grow from $3.01 billion in 2024 to $3.26 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to an increase in sexual activity, improving healthcare infrastructure, government initiatives, and funding, growing awareness and screening programs, and an increasing prevalence of chlamydia infections.

The chlamydia infection treatment market size is expected to see strong growth in the next few years. It will grow to $4.42 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to awareness campaigns, high healthcare expenditure, rising incidence in young adults, regulatory approvals, expanding healthcare infrastructure, and rising incidence of antibiotic resistance. Major trends in the forecast period include advancements in diagnostic technologies, development of point-of-care tests, collaborations and partnerships, development of effective treatment options, and technological advancement.

The forecast of 7.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. antibiotic stewardship by inflating prices of doxycycline tablets and single-dose azithromycin packs developed in Canada and Switzerland, resulting in treatment delays and higher community health center costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of sexually transmitted diseases (STDs) is anticipated to drive growth in the chlamydia infection treatment market. STDs are infections commonly spread through sexual contact, including vaginal, anal, or oral sex. This rise in STD rates is attributed to inconsistent or incorrect use of barrier methods like condoms, insufficient awareness and education on safe sex practices, and potential reductions in public health funding for prevention initiatives. Chlamydia infection diagnostics and therapeutics are essential in managing STDs, as they support early detection and effective treatment, helping to prevent complications and reduce transmission. For example, in May 2024, a report from the World Health Organization, an intergovernmental organization based in Switzerland, highlighted that four curable STDs-syphilis, gonorrhea, chlamydia, and trichomoniasis-account for over 1 million infections daily. The report also indicated a rise in adult and maternal syphilis cases (1.1 million), along with related congenital syphilis cases.

Key players in the chlamydia infection treatment market are concentrating on developing advanced technological products, such as fully automated diagnostic instruments, to enhance the speed and precision of chlamydia detection, streamline laboratory workflows, and improve patient outcomes. These automated instruments can test for multiple infections, including Chlamydia trachomatis, Neisseria gonorrhea, and Trichomonas vaginalis, from a single sample. This broad approach boosts diagnostic accuracy and helps detect co-infections. For example, in May 2022, Becton, Dickinson, and Company launched the BD COR MX instrument, a fully automated, high-throughput molecular diagnostic platform for infectious disease testing in the US. Part of the BD COR System, this instrument integrates robotics and sample management software to automate the entire molecular lab process, from sample handling to delivering test results. The BD COR MX instrument's initial test, the BD CTGCTV2 molecular assay, detects the three most common non-viral STIs-Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis-in one test. This instrument has received FDA 510(k) clearance for this assay.

In April 2022, Chiricahua Community Health Centers Inc. (CCHCI), a US-based healthcare provider, partnered with The Body Agency Collective (TBAC) and Visby Medical, Inc. to enhance STI diagnosis and treatment. This collaboration will utilize a PCR diagnostic device, the sexual health click test, to identify three prevalent and treatable STIs in women, gonorrhea, chlamydia, and trichomoniasis. The Body Agency Collective (TBAC) is a US-based foundation focused on providing accessible sexual and reproductive health education, products, and services to women and girls. Visby Medical, Inc. is a US-based medical diagnostics firm specializing in chlamydia infection treatment.

Major companies operating in the chlamydia infection treatment market are Pfizer Inc., F. Hoffmann La-Roche Ltd, Merck & Co. Inc., AbbVie Inc, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical, Gilead Sciences, Mylan N.V., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr. Reddy's Laboratories Ltd, Lupin Limited, Zydus Cadila, Hetero Healthcare Limited

North America was the largest region in the chlamydia infection treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chlamydia infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chlamydia infection treatment market includes revenues earned by entities through diagnosis testing, antibiotic prescriptions, partner notification, follow-up testing, counseling, and education. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chlamydia Infection Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chlamydia infection treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for chlamydia infection treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chlamydia infection treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Chlamydia Infection Treatment Market Characteristics

3. Chlamydia Infection Treatment Market Trends And Strategies

4. Chlamydia Infection Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Chlamydia Infection Treatment Growth Analysis And Strategic Analysis Framework

6. Chlamydia Infection Treatment Market Segmentation

7. Chlamydia Infection Treatment Market Regional And Country Analysis

8. Asia-Pacific Chlamydia Infection Treatment Market

9. China Chlamydia Infection Treatment Market

10. India Chlamydia Infection Treatment Market

11. Japan Chlamydia Infection Treatment Market

12. Australia Chlamydia Infection Treatment Market

13. Indonesia Chlamydia Infection Treatment Market

14. South Korea Chlamydia Infection Treatment Market

15. Western Europe Chlamydia Infection Treatment Market

16. UK Chlamydia Infection Treatment Market

17. Germany Chlamydia Infection Treatment Market

18. France Chlamydia Infection Treatment Market

19. Italy Chlamydia Infection Treatment Market

20. Spain Chlamydia Infection Treatment Market

21. Eastern Europe Chlamydia Infection Treatment Market

22. Russia Chlamydia Infection Treatment Market

23. North America Chlamydia Infection Treatment Market

24. USA Chlamydia Infection Treatment Market

25. Canada Chlamydia Infection Treatment Market

26. South America Chlamydia Infection Treatment Market

27. Brazil Chlamydia Infection Treatment Market

28. Middle East Chlamydia Infection Treatment Market

29. Africa Chlamydia Infection Treatment Market

30. Chlamydia Infection Treatment Market Competitive Landscape And Company Profiles

31. Chlamydia Infection Treatment Market Other Major And Innovative Companies

32. Global Chlamydia Infection Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chlamydia Infection Treatment Market

34. Recent Developments In The Chlamydia Infection Treatment Market

35. Chlamydia Infection Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기